Ibrance resources for patients

Pfizer is committed to ensuring patients are satisfied with their IBRANCE + endocrine therapy (ET) and that they achieve the full benefits this treatment option can offer them. For this reason, we have created a series of patient-centred materials to help them understand both their metastatic breast cancer (mBC) disease and why IBRANCE is appropriate for them.

 IBRANCE: Your guide to treatment

“Your guide to treatment with IBRANCE” is a short but comprehensive booklet containing clear and patient friendly explanations of what IBRANCE is and how it works, how it should be taken and monitored, and possible side effects that may occur, together with tips on how to manage these. It also includes a side effects diary to track how the patients are doing on their IBRANCE therapy, and a complete blood count (CBC) reminder card to help them keep track of their scheduled blood tests.

Ibrance Patient Brochure

 

Reference:
1. IBRANCE® Summary of Product Characteristics.

PP-IBR-GBR-2212. February 2020

 IBRANCE + ET dosing trackers

To help patients ensure they are taking their IBRANCE therapy correctly, there is also a dosing tracker available to help them keep track of when to take their medication. There is a dosing tracker for both IBRANCE + letrozole and IBRANCE + fulvestrant.

AI Dosing Card Fulvestrant Dosing Card

 

Reference:
1. IBRANCE® Summary of Product Characteristics.

PP-IBR-GBR-2262. February 2020